STERIS (NYSE:STE) Director Mohsen Sohi Sells 4,058 Shares

STERIS plc (NYSE:STE) Director Mohsen Sohi sold 4,058 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total value of $956,795.24. Following the sale, the director directly owned 24,305 shares in the company, valued at approximately $5,730,632.90. The trade was a 14.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

STERIS Price Performance

STE opened at $236.25 on Thursday. The firm has a market capitalization of $23.03 billion, a PE ratio of 28.88 and a beta of 0.91. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.91 and a quick ratio of 1.35. The business’s 50-day moving average is $216.51 and its two-hundred day moving average is $224.71. STERIS plc has a 1 year low of $195.14 and a 1 year high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, beating the consensus estimate of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The business had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm posted $2.34 earnings per share. The company’s quarterly revenue was up 7.3% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Research analysts anticipate that STERIS plc will post 11.09 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, September 4th will be given a dividend of $0.69 per share. The ex-dividend date of this dividend is Friday, September 4th. This is a positive change from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 dividend on an annualized basis and a yield of 1.2%. STERIS’s dividend payout ratio is currently 30.81%.

Institutional Investors Weigh In On STERIS

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of STERIS by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock valued at $3,114,882,000 after acquiring an additional 73,014 shares during the period. State Street Corp increased its holdings in STERIS by 6.0% in the 4th quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock worth $1,169,957,000 after buying an additional 260,001 shares during the period. Geode Capital Management LLC raised its position in STERIS by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after buying an additional 14,151 shares during the last quarter. Orbis Allan Gray Ltd raised its position in STERIS by 5.6% during the 4th quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock worth $570,296,000 after buying an additional 120,200 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in STERIS by 25.7% during the 1st quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock worth $411,995,000 after buying an additional 380,504 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. KeyCorp cut their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Wall Street Zen upgraded STERIS from a “hold” rating to a “buy” rating in a research note on Sunday. Piper Sandler reaffirmed an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Finally, UBS Group decreased their price target on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and an average target price of $271.33.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.